Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 18/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 18/20 | 1.00 |
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CDK4 | P11802 | 13/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 10/20 | 1.00 |
| ▸ | CDK1 | P06493 | 10/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 10/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 10/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 0.71 |
| ▸ | CCND2 | P30279 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040956 | 0.91 | CCNE2 (0.83) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5213493 | 0.89 | CCNE2 (0.80) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL14394597 | 0.87 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL14394613 | 0.85 | CDK2 (0.73) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5212998 | 0.85 | CDK2 (0.74) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6695938 | 0.84 | CCNE2 (0.76) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL14394714 | 0.83 | CCNE2 (0.71) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4734684 | 0.83 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL14373665 | 0.82 | CDK2 (0.76) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL14394461 | 0.81 | CCNE2 (0.73) | CCNE2CCNE1CDK2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042307-B1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2007-10-03 | — | — | EP | claimed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-1042307-B1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2007-10-03 | — | — | EP | disclosed |
| US-6521759-B2 | Anticancer, antiarthritic, and antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-1042307-A4 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | KIM KYOUNG S (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1240153-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6262096-B1 | IN COMBINATION WITH A MODULATOR OF P53 TRANSACTIVATION FORMULATED AS A FIXED DOSE. | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| WO-2001044217-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1042307-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6040321-A | ENZYME INHIBITOR TREATING CANCER, INFLAMMATION AND ARTHRITIS, NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, CARDIOVASCULAR DISEASES, VIRAL DISEASES AND FUNGAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999024416-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | CCNE2 1725/4885CCNE1 770/4885CDK2 109/4885 |
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | CCNI, CDK1, CCNK | CCNE2 14/4885CCNE1 5/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.